-
Testing Psychedelics Efficacy On 'Psychiatry's Blind Spot': Latest King's College Trial
Monday, February 13, 2023 - 2:30pm | 599Read More...A new open-label study Sponsored by King’s College London (KCL) will assess the effects of a single psilocybin dose of 25 milligram on subjects with a diagnosis of the common and disabling Functional Neurological Disorder (FND). The National Institutes of Health (NIH) defines this...
-
Study From King's College London Shows CBD Can't Reduce Negative Effects Of Cannabis, But It Can Make You Cough More
Thursday, November 17, 2022 - 12:41pm | 921Read More...Can CBD minimize some of the negative effects of marijuana? According to new research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London, no, it can’t. The study, published in Neuropsychopharmacology examined whether marijuana with higher...
-
Magic Mushrooms to Treat Anorexia? All About Compass' Novel Phase 2 Trial Of Psychedelic's Main Compound
Thursday, July 28, 2022 - 4:05pm | 644Read More...Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa. The trial will compare the effects of 25 mg and 1 mg of COMP360 (...
-
New Study To Evaluate Magic Mushroom's Therapeutic Potential On Autistic Adults
Monday, May 9, 2022 - 10:13am | 265Read More...Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults. The study, named Psilaut, is being co-sponsored by the...
